The role of the marker of multidrug resistance Pgp in the prediction of drug therapy of breast cancer
https://doi.org/10.18027/2224-5057-2016-2-15-21
Abstract
Breast cancer ranks first among all cancers in women in the world. Despite the great achievements of complex treatment, there is a category of patients is not sensitive to drug therapy. One of the reasons for the lack of effect of drug therapy in patients with breast cancer may be multi-drug resistance. The article presents the experience of the use of the marker of multidrug resistance Pgp, as a predictive factor for the effectiveness of the proposed chemotherapy.
About the Authors
Denis Anatolievich Ryabchikov
FEDERAL state scientific institution Russian oncological scientific center named. N. N. Blokhin,
Russian Federation
Russian Federation
MD, PhD, senior researcher of the surgical Department № 5
Igor Konstantinovich Vorotnikov
FEDERAL state budgetary institution Russian oncological scientific center named. N. N. Blokhin
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, head.surgical Department No. 5
Sergej Mihajlovich Portnoj
FEDERAL state budgetary institution Russian oncological scientific center named. N. N. Blokhin
Russian Federation
Russian Federation
MD, PhD, DSc, head.surgical Department No. 8
Nino Valer’yanovna Chkhikvadze
FEDERAL state budgetary institution Russian oncological scientific center named. N. N. Blokhin
Russian Federation
Russian Federation
MD, PhD, doctor of the surgical Department № 5
Aleksej Sergeevich Shusharin
FEDERAL state budgetary institution Russian oncological scientific center named. N. N. Blokhin
Russian Federation
Russian Federation
Intern
Maria Valer’evna Rodionova
FSBI scientific center for obstetrics, Minekologii and Perinatology academician V. I. Kulakov Ministry of health Russian Federation
Russian Federation
oncologist surgical Department of breast pathology
Russian Federation
oncologist surgical Department of breast pathology
Olga Aleksandrovna Anurova
FEDERAL state budgetary institution Russian oncological scientific center named. N. N. Blokhin
Russian Federation
Russian Federation
MD, PhD, leading researcher of the Department of human pathology
References
1. Visvander J. E., Lindeman G. J. Cell Stem Cell. 2012; 10(5): 717–728.
2. Аксель Е. М. Злокачественные образования молочной железы: Состояние онкологической помощи, заболеваемость и смертность. Маммология. 2006; 1: 9–15. Axel E. M. Malignant tumors of the breast: State of cancer care, morbidity and mortality. Mammalogy. 2006; 1: 9–15.
3. Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. М.: Издательская группа РОНЦ. 2014: 46. Davydov M. I., Aksel E. M. Statistics of malignant neoplasms in Russia and CIS in 2012. M.: Publishing group, cancer research center. 2014: 46.
4. Calcagno A. M., Salcido C. D., Gillet J. P. et al. Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. J Natl Cancer Inst 2010;102(21):1637–52.
5. Saxena M., Stephens M. A., Pathak H., Rangarajan A. Transcription factors that mediate epithelialmesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dif 2011;2:179.
6. Ставровская А. А., Генс Г. П. Некоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клеток. Успехи молекулярной онкологии. 2014; 1: 5–11. Stavrovskaya A. A., gens G. P. Some new aspects of studies of multidrug resistance of tumor cells. The successes of molecular Oncology. 2014; 1: 5–11.
7. Ставровская А. А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток. Биохимия. 2000; 65(1): 112–26. Stavrovskaya A. A., Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry. 2000; 65(1): 112–26.
8. М. А. Барышникова, Д. А. Афанасьева, И. В. Уласов, А. Ю. Барышников. Механизмы лекарственной устойчивости меланомы. Российский биотерапевтический журнал. 2015; 2(14): 17–23. Baryshnikova M. A., Afanasyev D. A., Ulasov I. V., Baryshnikov A. Y. Mechanisms of drug resistance of melanoma. The Russian biotherapeutic journal. 2015; 2(14): 17–23.
9. Ставровская А. А., Стромская Т. П. Транспортные белки семейства АВС и множественная лекарственная устойчивость опухолевых клеток. Биохимия. 2008; 73(5): 735–50. Stavrovskaya A. A., Stromskaya T. P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry. 2008; 73(5): 735–50.
10. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The Role of ABC Transporters in Drug Resistance, Metabolism, and Toxicity. Current Drug Delivery. 2004; 1(1): 1–16.
11. Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361–98.
12. Лавникова Г. А., Некоторые закономерности лучевого патоморфоза опухолей человека и их практическое использование. Вестник АМН СССР. 1976; 6:13–19. Lavnikova G. A. Some regularities of radiation pathomorphism of tumors and their practical use. Vestnik of the USSR AMS. 1976; 6:13–19.
13. Federici C., Petrucci F., Caimi S. et al. Exosome Release and Low pH Belong to a Framework of Resistance of HumanMelanoma Cells to Cisplatin. PLoS ONE. 2014; 9(2): 881–93.
14. Dyszlewski M., Blake H. M., Dahlheimer J. L., Pica C. M., Piwnica-Worms D. Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol Imaging. 2002; 1(1):24–35.
15. Ciarmiello A., Del Vecchio S., Silvestro P., Potena M. I., Carriero M. V., Thomas R., Botti G., D’Aiuto G., Salvatore M. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16(5):1677–83.
16. Chintamani A., Jai Parakash Singh, Mahesh K Mittal, Sunita Saxena, Anju Bansal, Ashima Bhatia and Pranjal Kulshreshtha. World Journal of Surgical Oncology. 2005; 3(3):61.
Review
For citations:
Ryabchikov D.A., Vorotnikov I.K., Portnoj S.M., Chkhikvadze N.V., Shusharin A.S., Rodionova M.V., Anurova O.A. The role of the marker of multidrug resistance Pgp in the prediction of drug therapy of breast cancer. Malignant tumours. 2016;(2):15-21. (In Russ.) https://doi.org/10.18027/2224-5057-2016-2-15-21
Views:
911
Email this article 